熱門詞： 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
熱門詞： 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
Pro-Cure Therapeutics 英國Pro-Cure Therapeutics Limited (Pro-Cure)
從大學(xué)的癌癥研究所內(nèi)部發(fā)展出來的一家企業(yè)，從事前列腺癌基因療法的研究。
Pro-Cure Therapeutics Limited (Pro-Cure) is a UK-based R&D company that is focused on cancer stem cell therapies - with an initial interest in prostate cancer stem cells.
Founded on the work of Professor Norman Maitland and Dr Anne Collins of the Yorkshire Cancer Research (YCR) Cancer Research Unit (CRU) at York University, the Company has identified drug targets for new classes of cancer drugs that fundamentally change the management of prostate cancer by preventing cancer stem cells' ability to initiate new tumours, to prevent recurrence, prevent metastasis and as an effective treatment for drug-resistant forms of prostate cancer.
Pro-Cure seeks alliances with companies to develop new therapeutics against these exciting new targets. Pro-Cure is pursuing MAb approaches to selected targets but targets are also identified that are suited to other therapeutic technologies such as small molecules (different classes of receptors and targets have been identified including common drug targets such as kinases, proteases, etc.), siRNA and peptides. We also have other targets in validation that are suited to antibody therapies and vaccines.
知識(shí)產(chǎn)權(quán)侵權(quán)投訴：不生產(chǎn)任何產(chǎn)品所有產(chǎn)品均來自產(chǎn)品的生產(chǎn)廠商、代理商、經(jīng)銷商，如有侵權(quán)請(qǐng)聯(lián)系：400-006-7520 ，我們會(huì)在第一時(shí)間處理
本網(wǎng)站所有產(chǎn)品與藥品無關(guān)
滬公網(wǎng)安備31011502016460號(hào)
